Cellular targets in diabetic retinopathy therapy.

World J Diabetes

Department of Physiology, Faculty of Pharmacy, University of Valencia, Burjassot 46100, Valencia, Spain.

Published: September 2021

Despite the existence of treatment for diabetes, inadequate metabolic control triggers the appearance of chronic complications such as diabetic retinopathy. Diabetic retinopathy is considered a multifactorial disease of complex etiology in which oxidative stress and low chronic inflammation play essential roles. Chronic exposure to hyperglycemia triggers a loss of redox balance that is critical for the appearance of neuronal and vascular damage during the development and progression of the disease. Current therapies for the treatment of diabetic retinopathy are used in advanced stages of the disease and are unable to reverse the retinal damage induced by hyperglycemia. The lack of effective therapies without side effects means there is an urgent need to identify an early action capable of preventing the development of the disease and its pathophysiological consequences in order to avoid loss of vision associated with diabetic retinopathy. Therefore, in this review we propose different therapeutic targets related to the modulation of the redox and inflammatory status that, potentially, can prevent the development and progression of the disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472497PMC
http://dx.doi.org/10.4239/wjd.v12.i9.1442DOI Listing

Publication Analysis

Top Keywords

diabetic retinopathy
20
development progression
8
progression disease
8
diabetic
5
retinopathy
5
disease
5
cellular targets
4
targets diabetic
4
retinopathy therapy
4
therapy despite
4

Similar Publications

Background: Glaucoma, diabetic retinopathy, and age-related macular degeneration impose substantial economic burdens on healthcare systems due to their high prevalence and chronic nature. Nevertheless, comprehensive Italian data is limited. This study aims to collect Italian evidence on the economic impact of these conditions to support more effective healthcare planning.

View Article and Find Full Text PDF

Diabetic retinopathy, a microvascular complication of diabetes, is the leading cause of blindness in adults, but the molecular mechanism of its development remains unclear. Retinal mitochondrial DNA is damaged and hypermethylated, and mtDNA-encoded genes are downregulated. Expression of a long noncoding RNA (larger than 200 nucleotides, which does not translate into proteins), encoded by mtDNA, cytochrome B (Lnc), is also downregulated.

View Article and Find Full Text PDF

Eye Axial Length: Is There a Protective Link to Diabetic Retinopathy?

Cureus

December 2024

Optics and Optometry Division, Investigative Techniques in Optometry Research Group, Department of Biomedical Sciences, University of West Attica, Athens, GRC.

Diabetic retinopathy (DR) is a leading cause of vision impairment and blindness globally, particularly among working-age adults. As the prevalence of diabetes continues to rise, understanding factors that influence DR development and progression is increasingly important. Recent studies suggest a protective association between a longer axial length (AL) of the eye and the risk of DR, particularly in myopic individuals.

View Article and Find Full Text PDF

In human eye, structural proteins, known as crystallins, play a crucial role in maintaining the eye's refractive index. These crystallins constitute majority of the total soluble proteins found in the eye lens. Among them, α-crystallins (α-CR) is one of the major components.

View Article and Find Full Text PDF

A Bifunctional Peptide with Penetration Ability for Treating Retinal Angiogenesis via Eye Drops.

Mol Pharm

January 2025

Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate-based Medicine, Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, 44 Wenhua West Road, Jinan 250012, China.

Numerous diseases, such as diabetic retinopathy and age-related macular degeneration, can lead to retinal neovascularization, which can seriously impair the visual function and potentially result in blindness. The presence of the blood-retina barrier makes it challenging for ocularly administered drugs to penetrate physiological barriers and reach the ocular posterior segments, including the retina and choroid. Herein, we developed an innovative bifunctional peptide, Tat-C-RP7, which exhibits excellent penetration capabilities and antiangiogenic properties aimed at treating retinal neovascularization diseases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!